Forbes contributors publish independent expert analyses and insights. I write about college football and sports in the Tampa Bay region. This voice experience is generated by AI. Learn more. This ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

This combination was associated with high response rates and durable remissions, with an acceptable safety, in heavily pretreated patients with AML harboring alterations susceptible to menin ...

The Global Hypertension Report by the World Health Organization (WHO) revealed that 1.4 billion people were living with hypertension in 2024. Yet, only a little over one in five of those diagnosed ...

If you explore off the beaten track, you'll find plenty of 007 First Light safe codes. The problem is, some of them are trickier to unlock than others. Most safes are optional, but unlocking them will ...

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL). This is an ASCO Meeting ...

Writing from the Chicagoland area in Illinois, Robert is an avid movie watcher and will take just about any excuse to find time to go to his local movie theaters. Robert graduated from Bradley ...

Algorae Pharmaceuticals Ltd (ASX:1AI, OTC:LVCLF, FRA:LHI0) has completed the prediction-generation phase of a multi-anchor drug combination program using its AlgoraeOS v2 (AOS2) artificial ...

In Vampire Crawlers: The Turbo Wildcard from Vampire Survivors, evolutions are the best way to obtain stronger cards. By combining two base cards according to their evolution recipe, you can get a ...

Tucked away in the English countryside, Bletchley Park looked like just another stately home - but inside, a silent war was being fought. Here, mathematicians, engineers, and codebreakers worked ...

Combined treatment with both a GLP-1 receptor agonist (GLP-1RA) and an SGLT2 inhibitor was linked to lower all-cause mortality and a lower risk for some cardiovascular outcomes, new research showed.